Brazikumab Emerging Drug Insight

“Brazikumab Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Brazikumab for Crohn’s disease (CD) in the 7MM. A detailed picture of the Brazikumab for Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Brazikumab for Crohn’s disease (CD). The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Brazikumab market forecast, analysis for Crohn’s disease (CD) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn’s disease (CD).

Drug Summary

Brazikumab (MEDI-2070), formerly known as AMG-139, was developed in 2012 by the collaboration of AstraZeneca and Amgen for the treatment of inflammatory diseases. Brazikumab is a monoclonal antibody that binds to the IL23 receptor and is in development for CD and UC with a companion biomarker. Brazikumab selectively blocks the IL23 immune signal, preventing intestinal inflammation.

Brazikumab is currently in the Phase III clinical development stage for the treatment of Crohn’s Disease and in the Phase II clinical stage development for the treatment of Ulcerative Colitis. In Phase II trials, Brazikumab demonstrated a clinical effect at week eight in tumor necrosis factor-resistant CD patients. The Phase IIb/III INTREPID program is underway to assess Brazikumab compared to placebo or Adalimumab in Crohn’s Disease.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the Brazikumab description, mechanism of action, dosage and administration, research and development activities in Crohn’s disease (CD).
•  Elaborated details on Brazikumab regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the Brazikumab research and development activity in Crohn’s disease (CD) in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around Brazikumab.
•  The report contains forecasted sales of Brazikumab for Crohn’s disease (CD) till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Crohn’s disease (CD).
•  The report also features the SWOT analysis with analyst views for Brazikumab in Crohn’s disease (CD).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Brazikumab Analytical Perspective by DelveInsight

• In-depth Brazikumab Market Assessment

This report provides a detailed market assessment of Brazikumab in Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• Brazikumab Clinical Assessment

The report provides the clinical trials information of Brazikumab in Crohn’s disease (CD) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Crohn’s disease (CD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Brazikumab dominance.
•  Other emerging products for Crohn’s disease (CD) are expected to give tough market competition to Brazikumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Brazikumab in Crohn’s disease (CD).
•  Our in-depth analysis of the forecasted sales data of Brazikumab from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Brazikumab in Crohn’s disease (CD).

Key Questions

•  What is the product type, route of administration and mechanism of action of Brazikumab?
•  What is the clinical trial status of the study related to Brazikumab in Crohn’s disease (CD) and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Brazikumab development?
•  What are the key designations that have been granted to Brazikumab for Crohn’s disease (CD)?
•  What is the forecasted market scenario of Brazikumab for Crohn’s disease (CD)?
•  What are the forecasted sales of Brazikumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Crohn’s disease (CD) and how are they giving competition to Brazikumab for Crohn’s disease (CD)?
•  Which are the late-stage emerging therapies under development for the treatment of Crohn’s disease (CD)?